With regards to osteosarcoma, single immune checkpoint inhibition is of limited value but the combination of anti-PDL-1 and TILs therapy in metastatic disease, showed safety and effectiveness, in two retrospective studies published in 2020 (106, 107). This evidence concerns the gene CD274 and metastatic neoplasm.